Elizabeth Mittendorf, MD, PhD, Assistant Professor in the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center, discusses the potential to target cyclin E in breast cancer.
Cyclin E is an important cell cycle regulator, Mittendorf says, and it has been discovered that it can be cleaved into low molecular weight (LMW) isoforms. These LMW isoforms are tumor-specific and cause cells to be less susceptible to inhibition and proliferate through the cell cycle more rapidly.
From a disease standpoint, LMW cyclin E is associated with a poor prognosis, meaning that it could be a target, though this is still be pursued. Mittendorf says that she views cyclin E slightly differently and says that it could be a target for immunotherapy because of its overexpression and abnormal expression in breast cancer.
This preclinical observation has been published and Mittendorf says that a decision needs to be made as to whether or not to pursue cyclin E as a therapeutic strategy.